Loading
A phase 3 trial of Pembrolizumab, Doxorubicin, Epirubicin and Cyclophosphamide in HR-positive / HER2-negative breast cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) is a phase 3 interventional study registered as NCT03725059 by Merck Sharp & Dohme LLC, with 1240 participants enrolled, started 2018-12-27 and due to reach its primary completion in 2031-01-24. Interventions recorded: Pembrolizumab (K), Placebo (P), Paclitaxel (X), Doxorubicin (A), Epirubicin (E) and Cyclophosphamide (C).
Shares Epirubicin, Doxorubicin, Cyclophosphamide, Merck & Co. (MSD) and the tag pipeline.
Shares Epirubicin, Doxorubicin, Cyclophosphamide, Merck & Co. (MSD) and the tag pipeline.
Shares Epirubicin, High-risk early HR-positive breast cancer, Cyclophosphamide, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Epirubicin, Doxorubicin, Cyclophosphamide, Pembrolizumab and the tag pipeline.
Shares Doxorubicin, Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Doxorubicin, Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.